GlassScriptPhysician profile
Diala Manfoukh
NPI 1033843222
$8,620.04
in general payments reported to CMS, 2019-2025
47 companies · $4,546 in 2025
The $4,546 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $4,074 · 2025: $4,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,308 · Education: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,307.55 |
| Education | $312.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,186.92 | 2024-2025 | |
| Pfizer INC. | $735.75 | 2024-2025 | |
| Eisai INC. | $659.54 | 2024-2025 | |
| Ucb, INC. | $653.06 | 2024-2025 | Rystiggo, Fintepla, Briviact |
| Lilly USA, LLC | $489.29 | 2024-2025 | Kisunla, Emgality, Reyvow |
| Jazz Pharmaceuticals INC. | $422.68 | 2024-2025 | |
| Axsome Therapeutics, INC. | $411.77 | 2024-2025 | Symbravo, Sunosi |
| Argenx US, INC. | $271.23 | 2024-2025 | Vyvgart Hytrulo |
| C2n Diagnostics, LLC | $260.42 | 2025 | Precivityad2 |
| Neurocrine Biosciences, INC. | $227.72 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $224.05 | 2024-2025 | Rexulti |
| Emd Serono, INC. | $221.75 | 2024-2025 | |
| Biogen, INC. | $197.32 | 2024-2025 | Tysabri, Vumerity |
| Averitas Pharma INC. | $195.01 | 2024-2025 | Qutenza |
| Astrazeneca Pharmaceuticals LP | $182.96 | 2024-2025 | Wainua |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $153.94 | 2025 | |
| Amneal Pharmaceuticals LLC | $153.13 | 2024-2025 | Crexont, Rytary |
| Lundbeck LLC | $147.74 | 2024-2025 | Vyepti, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $144.35 | 2024 | Hyqvia |
| Medtronic, INC. | $144.27 | 2024-2025 | Percept PC Brainsense, Intellis Adaptivestim |
| Ipsen Biopharmaceuticals, INC | $140.00 | 2025 | Dysport |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2024 | Zeposia |
| Mallinckrodt Hospital Products INC. | $122.13 | 2024-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $106.13 | 2024-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $94.79 | 2024-2025 | Austedo Xr |
| Avadel Cns Pharmaceuticals, LLC | $93.26 | 2025 | Lumryz |
| Genentech USA, INC. | $86.10 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Alnylam Pharmaceuticals INC. | $76.32 | 2024 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $70.19 | 2025 | |
| Neurelis, INC. | $68.60 | 2025 | Valtoco |
| Grifols USA, LLC | $64.75 | 2025 | Gamunex-C |
| Merz Pharmaceuticals, LLC | $50.31 | 2024-2025 | Xeomin, Inbrija |
| Inspire Medical Systems, INC. | $48.12 | 2024 | Inspire |
| Abbott Laboratories | $46.26 | 2024-2025 | Eterna, Amplatzer Talisman |
| Amgen INC. | $43.76 | 2024-2025 | Uplizna |
| Celgene Corporation | $40.32 | 2025 | Zeposia |
| Tanabe Pharma America, INC. | $36.58 | 2024 | |
| Ge Healthcare | $36.54 | 2024-2025 | |
| Cycle Pharmaceuticals INC | $31.02 | 2025 | Bafiertam, Tascenso Odt |
| Avid Radiopharmaceuticals, INC. | $27.59 | 2025 | |
| Sk Life Science, INC. | $23.81 | 2025 | |
| Acadia Pharmaceuticals INC | $22.99 | 2024 | Nuplazid |
| Janssen Biotech, INC. | $21.30 | 2025 | |
| Impel Pharmaceuticals LLC | $17.02 | 2025 | Trudhesa |
| Tonix Medicines, INC. | $16.32 | 2025 | Zembrace Symtouch |
| Boston Scientific Corporation | $14.01 | 2024 | Lux-Dx Insertable Cardiac Monitor |
| Azurity Pharmaceuticals, INC. | $13.92 | 2024 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diala Manfoukh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.